News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
Isis Pharma (ISIS) Reports Data From ISIS-TTR Rx In Patients With Transthyretin Amyloid-Related Cardiomyopathy 7/27/2015
Eli Lilly (LLY) Provides Update On Evacetrapib Phase 3 Trial 7/27/2015
Bellerophon Therapeutics (BLPH) Heart Device Flunks Key Study 7/27/2015
AcelRx (ACRX) Announces Positive CHMP Opinion For Zalviso In The Management Of Acute Moderate-To-Severe Post-Operative Pain In Adult Patients 7/24/2015
As Biogen (BIIB), Eli Lilly (LLY) Fall Short, Roche (RHHBY) Intensifies Work on Two Alzheimer's Drugs 7/23/2015
Amgen (AMGN) Submits Supplemental New Drug Application For Kyprolis (Carfilzomib) In Relapsed Multiple Myeloma 7/23/2015
PharmaMar S.A. Announces License Agreement With TTY Biopharm For APLIDIN (plitidepsin) In Hematological Cancers 7/23/2015
Biogen (BIIB) and Eli Lilly (LLY)’s Alzheimer’s Drugs Hint At Promise, But Fail To Dazzle 7/23/2015
AstraZeneca PLC (AZN)'s Selumetinib Flunks Phase III Eye Cancer Study 7/22/2015
Bay Area's XOMA (US) LLC (XOMA) Crashes on Disappointing Phase III Data 7/22/2015
Intra-Cellular Therapies, Inc. Announces Phase III Clinical Development Program For The Treatment Of Depressive Episodes Associated With Bipolar Disorder (Bipolar Depression) 7/22/2015
Clinical Trials Results And New Data Analyses In Amyloid-related Therapies From The Alzheimer's Association International Conference 2015 7/22/2015
Eli Lilly (LLY) Release: Data Using New Delayed-Start Methodology Suggested Benefit Of Early Treatment With Solanezumab In Patients With Mild Alzheimer's Disease 7/22/2015
Gilead (GILD) Announces Phase III Results From The First Study To Evaluate Switching From TDF-Based Regimens To A TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine And Tenofovir Alafenamide (E/C/F/TAF) 7/22/2015
Shire plc Release: Vyvanse (lisdexamfetamine dimesylate) Positive Top-Line Results In Maintenance Of Efficacy Study In Adults With Moderate To Severe Binge Eating Disorder 7/22/2015
Investors Excited Over Eli Lilly (LLY) and Biogen (BIIB)'s Upcoming Alzheimer’s Drug Data 7/21/2015
Onxeo: Update On ReLive, Livatag International Phase III Clinical Trial In HCC 7/21/2015
BioTie Therapies Corp. Announces Start Of Tozadenant Phase 3 Study In Parkinson's Disease 7/21/2015
Bristol-Myers Squibb (BMY)'s Opdivo Phase III Study Stopped Early on More Good Cancer Therapy News 7/21/2015
Embattled Exelixis (EXEL) Nabs Much-Needed Victory for Phase III Renal Cell Carcinoma Study 7/21/2015
Why All Eyes Will Be on Biogen (BIIB)'s Alzheimer's Data Next Week 7/20/2015
Telesta Therapeutics Announces South Korean Partnership For MCNA & Concurrent Private Placement 7/20/2015
Alnylam (ALNY) Initiates Phase III Open Label Extension Study (“APOLLO-OLE”) With Patisiran, An Investigational Rnai Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR Amyloidosis) 7/20/2015
Cartiva Announces Positive Final Data From Its Cartiva SCI Pivotal Trial For Great Toe Arthritis 7/17/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Korean Licensee Receives Government Approval To Conduct Phase 2b/3 Clinical Trial In Patients With Dry Eye Syndrome 7/17/2015
Carbylan Therapeutics Provides Timeline Update For Phase III Clinical Program 7/16/2015
Anacor (ANAC) Hits Home Run with Crisaborole Phase III Trials, Predicts $1 Billion Potential Sales 7/15/2015
Rockwell Medical (RMTI) Announces Triferic Phase III CRUISE Studies Published In Nephrology Dialysis Transplantation 7/15/2015
Argos Therapeutics, Inc. (ARGS) Announces Completion Of Patient Enrollment In Pivotal Phase III ADAPT Clinical Trial Of AGS-003 7/15/2015
CytoDyn Release: Evidence Of HIV Suppression With PRO 140 Monotherapy Reaching Nearly 11 Months 7/15/2015
Executive Shuffle and Alzheimer’s Drug Report Creates a Rocky Road for Biogen (BIIB) Stock 7/14/2015
Accera, Inc. Reaches 75% Enrollment In The Phase 3 NOURISH AD Study Of AC-1204 For The Treatment Of Alzheimer's Disease 7/14/2015
Isis Pharma (ISIS) Earns $2.15M For Advancing ISIS-SMN Rx In Children With Spinal Muscular Atrophy 7/14/2015
Cytokinetics, Inc. (CYTK) And The ALS Association Announce Awarding Of Grant For Phase 3 Clinical Trial And Biomarker Research Collaboration 7/14/2015
JAMA Publishes Long-Term Safety And Efficacy Results Of Trial With Relypsa (RLYP)'s Patiromer FOS Over One Year 7/14/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Custirsen Phase 3 "ENSPIRIT Trial Continues Following Completion Of Final Futility Survival Analysis 7/13/2015
CureMark Secures $20 Million In Equity Financing 7/13/2015
Anacor (ANAC) Announces Positive Top-Line Results From Two Phase III Pivotal Studies Of Crisaborole Topical Ointment, 2% In Patients With Mild-To-Moderate Atopic Dermatitis 7/13/2015
Pierre Fabre Release: Bladder Cancer Patients And Doctors Disappointed By Scottish Medicines Consortium's Negative Decision On Javlor (Vinflunine As Ditartrate) For The Treatment Of Adult Patients 7/13/2015
Adamas Pharmaceuticals (ADMS) Completes Recruitment Of Its Phase III EASE LID Study Evaluating ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease 7/10/2015
Opko Health (OPK) Announces Completion Of Enrollment In Phase III Trial Of Hgh-CTP In Growth Hormone Deficient Adults 7/10/2015
BIO2015 EXCLUSIVE: BioSpace (DHX)’s Insider Profile of Neovacs SA 7/9/2015
Regeneron (REGN), Sanofi (SAN.PA)'s Praluent Delivers in Late Stage Trial 7/9/2015
EXCLUSIVE: Thrasos May Seek Breakthrough Status for Kidney Injury Drug, CEO Says 7/9/2015
Anika Therapeutics (ANIK) Announces Positive Results From Follow-Up Study Evaluating Safety Of A Repeat Injection Of CINGAL For Treatment Of Osteoarthritis Of The Knee 7/9/2015
Dynavax Technologies Corporation (DVAX) Announces Third Independent DSMB Recommendation To Continue Phase 3 Study Of HEPLISAV-B(TM) And Updates Financial Status 7/9/2015
Regeneron (REGN) And Sanofi (SAN.PA) Announce Phase III Results Showing LDL-C Reductions Of More Than 60 Percent In Japanese Patients Treated With Praluent(Alirocumab) Injection 7/9/2015
AstraZeneca PLC (AZN) And Ironwood (IRWD) Report Positive Top-Line Data From Phase III IBS-C Trial Designed To Support Linaclotide Approval In China 7/8/2015
EXCLUSIVE: DNAnexus, Stanford University Genomic Catalog Will Accelerate Science in the Field, Says CEO 7/8/2015
Genentech (RHHBY)'s Ocrelizumab Wows in Late Stages and Eyes $18 Billion MS Market 7/7/2015
Cempra Pharmaceuticals, Inc. (CEMP) Completes Patient Enrollment Of Solitaire-IV Phase III Clinical Trial 7/7/2015
Progenics Pharmaceuticals, Inc. (PGNX) Announces Plans To Move Forward With 1404 Phase III Trial 7/7/2015
Accelovance Completes Trial Enrollment And Delivery Of Clinical Data For Heron (HRTX)' Phase 3 Trial 7/7/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Establishes Agreement With Novella Clinical To Conduct ICT-107 Phase 3 Registration Trial In Glioblastoma 7/6/2015
Akcea Therapeutics Receives Orphan Drug Designation From The US FDA For Volanesorsen (ISIS-APOCIII Rx) For The Treatment Of Familial Chylomicronemia Syndrome 7/6/2015
RedHill Biopharma Ltd. (RDHL) Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104 7/6/2015
Boehringer Ingelheim Release: Phase III Data Published In The Lancet Oncology Shows A Significant Overall Survival Benefit Of Giotrif (Afatinib) Compared To Tarceva(Erlotinib) 7/6/2015
Versartis, Inc. (VSAR) Announces Removal Of FDA Partial Clinical Hold And Continuation Of VRS-317 Phase III Clinical Trial 7/6/2015
AcelRx (ACRX) Release: Zalviso Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain 7/2/2015
Cortendo: Cortendo Provides 2015 Half-Year Update On Corporate Progress 7/2/2015
Viventia Biotech Inc. (VBI.TO) Begins Recruitment Of Clinical Centers As It Prepares To Initiate Phase III Clinical Trial Of Vicinium For The Treatment Of Non-Muscle-Invasive Bladder Cancer 7/2/2015
XBiotech USA (XBIT) Conducts Investigators Meeting To Update The Status Of Its Phase III Registration Study Underway In Europe 7/1/2015
Cerespir Submits Special Protocol Assessment Request To FDA For A Phase III Clinical Trial To Test The Ability Of CSP-1103 To Slow The Progression Of Mild Cognitive Impairment Due To Alzheimer's Disease 7/1/2015
CEL-SCI (CVM) Reports June Patient Enrollment in Its Phase III Head And Neck Cancer Trial 7/1/2015
PRANA Biotechnology (PRAN) Announces Safety Outcomes Of Alzheimer’s IMAGINE Extension Trial 7/1/2015
Genentech (RHHBY)’s Ocrelizumab Significantly Reduced Both Relapses And Disability Progression Versus Interferon Beta-1a (Rebif) In Two Phase III Studies In Multiple Sclerosis 6/30/2015
AEterna Zentaris (AEZS) Completes Patient Recruitment For ZoptEC Phase 3 Study With Zoptarelin Doxorubicin In Advanced Endometrial Cancer 6/30/2015
Lipocine Inc. (LPCN)'s Oral Testosterone Well Tolerated In Phase III Study 6/30/2015
Neothetics Initiates Study To Evaluate The Post-Treatment Safety And Duration Of Clinical Effect Of LIPO-202 For Body Contouring 6/30/2015
AVANIR Pharmaceuticals (AVNR) Announces Positive Top-Line Results From Stroke And TBI Cohorts Of PRISM II Study 6/30/2015
Zhejiang Kanglaite To Start US Phase III Trial Of TCM Cancer Drug 6/30/2015
ErgoMed’s Co-Development Partner AEterna Zentaris (AEZS) Completes Patient Recruitment For Zoptec Phase 3 Study With Zoptarelin Doxorubicin In Advanced Endometrial Cancer 6/30/2015
PharmaMar S.A. Initiates The Phase III Study CORAIL For The Anticancer Agent PM1183 In Patients With Platinum-Resistant Ovarian Cancer 6/29/2015
Enrollment In Relmada Therapeutics' Proof-Of-Concept Clinical Study For Novel Oral Formulations Of Buprenorphine Reaches Halfway Mark 6/29/2015
Independent Data Safety And Monitoring Board Recommends Continuation Of Celldex (CLDX)'s Phase III Study Of RINTEGA (Rindopepimut) In Newly Diagnosed Glioblastoma 6/29/2015
Merck & Co. (MRK) Announces Phase III Study Of Single-Dose EMEND® (Fosaprepitant Dimeglumine) For Injection Regimen Met Primary Endpoint In Prevention Of Chemotherapy-Induced Nausea And Vomiting In Patients Receiving Moderately Emetogenic Chemotherapy 6/29/2015
CytoTools Announces Positive Intermediate Results For The European Ulcus Cruris Trial – Seamless Transition Into An Approval-Relevant Phase III Trial With Less Number Of Patients 6/29/2015
Cynapsus Therapeutics (CYNAF) Enrolls First Patient In Pivotal Phase 3 Efficacy Study Evaluating Sublingual, Film Strip Delivery Of Apomorphine To Turn Parkinson’s Disease Patients From The OFF To The ON State 6/29/2015
AbbVie (ABBV)’s Viekira Pak Clears Another Hurdle, 100% HCV-1b Clearance Rate in Phase III Trial 6/25/2015
BioBlast Pharma (ORPN) Receives Orphan Drug Designation From The European Commission (EC) For Cabaletta For The Treatment Of Oculopharyngeal Muscular Dystrophy 6/25/2015
CSL Behring Presents rIX-FP For Hemophilia B Phase III Data Evaluating Efficacy, Safety And Improved Dosing At ISTH 2015 6/25/2015
AEterna Zentaris (AEZS) Announces Selection Of ErgoMed To Conduct Confirmatory Phase 3 Clinical Trial Of Macrilen In AGHD 6/25/2015
Allergy Therapeutics plc Release: To Resume U.S. Clinical Development Programme 6/25/2015
Teva (TEVA) And Active Biotech (BTPC) Announce Completion Of Patient Enrollment In Laquinimod Phase III CONCERTO Trial 6/25/2015
Wonder Drug Meets All Endpoints for Portola, Bristol-Myers Squibb (BMY) and Pfizer (PFE) 6/24/2015
Perle Bioscience Release: Insulin Independence Revolutionary Phase 3 Trial 6/24/2015
Celator Pharmaceuticals, Inc. Announces Positive Induction Response Results From Phase 3 Study Of CPX-351 In Patients With High-Risk (Secondary) Acute Myeloid Leukemia 6/24/2015
Novo Nordisk A/S (NVO) Release: In A Phase 3 Trial, Novoeight(Antihemophilic Factor [Recombinant]) Provided Long-Term Efficacy And Safety In The Prophylaxis And Treatment Of Bleeds In People With Hemophilia A 6/24/2015
Transition Therapeutics Inc. (TTH.TO) Announces Results Of Clinical Study Of ELND005 In Agitation And Aggression In Patients With Alzheimer's Disease 6/24/2015
Nuvo Research Inc. (NRI.TO) Provides Update On International Licensing Of Pennsaid 2% 6/24/2015
CSL Behring Announces Pivotal Data Of Novel rVIII-SingleChain Therapy In Adolescents And Adults With Hemophilia A 6/24/2015
GlycoMimetics, Inc. (GLYC) To Receive $20 Million Payment From Pfizer Following Initiation Of Phase III Trial With Rivipansel 6/24/2015
Tokai Pharmaceuticals (TKAI) Announces Initiation Of Phase 3 ARMOR3-SV Trial Of Galeterone In AR-V7 Positive Metastatic Castration-Resistant Prostate Cancer 6/24/2015
Amgen (AMGN) Brings in More Good News on Phase III Cancer Trial 6/23/2015
Caladrius Biosciences Announces First Patient Dosed In Phase 3 Immunotherapy Trial For Melanoma 6/23/2015
DURECT Corporation (DRRX) Announces Plans For A New POSIDUR (SABER-Bupivacaine) Clinical Trial 6/23/2015
Synta (SNTA) Announces Journal Publication Describing Complementary Activity Of Hsp90 Inhibition And Immune Checkpoint Blockade For Cancer Therapy 6/23/2015
Synergy Pharma Initiates Second Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation 6/23/2015
Pfizer (PFE) Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease 6/23/2015
Paratek Pharmaceuticals, Inc. Doses First Patient In Phase 3 Clinical Trial Of Omadacycline In Acute Bacterial Skin And Skin Structure Infections 6/23/2015
Intra-Cellular Therapies, Inc. Reports Initiation Of Randomization For ITI-007-302 Phase 3 Trial In Schizophrenia 6/23/2015
Boehringer Ingelheim Phase III Pradax Anticoagulant Antidote Study Meets Primary Endpoints 6/22/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Establishes Agreement With Pure MHC For Novel Quality Control Assay For ICT-107 Phase 3 Registrational Trial 6/22/2015
Ampio Pharmaceuticals, Inc. (AMPE) Announces Additional Statistically Significant Study Results For Optina In The Treatment Of Diabetic Macular Edema (DME) 6/22/2015
Resverlogix (RVX.TO) Officially Attains Phase 3 Status With A European Regulatory Authority 6/22/2015
FORUM Pharma Snags Fast Track Status for Encenicline to Treat Cognitive Impairment in Schizophrenia 6/22/2015
Synergy Pharma Becomes an Attractive Takeover Target After Drug Wows in Phase III Study 6/19/2015
Eli Lilly (LLY) Release: CYRAMZA (ramucirumab) Hepatocellular Carcinoma Data Published By The Lancet Oncology 6/19/2015
MedDay Reports Additional Positive Data Of Its Pivotal Phase III Study With MD1003 In Patients With Progressive Multiple Sclerosis 6/19/2015
Amgen (AMGN) Release: Results From Phase III Trial Show Vectibix (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care 6/19/2015
Radius Health (RDUS) Announces Positive Top-Line Data From ACTIVEExtend Trial Including Combined 25 Month Results 6/18/2015
Daiichi Sankyo Initiates Hokusai-VTE Cancer Study To Evaluate The Role Of Edoxaban In Patients With Venous Thromboembolism Associated With Cancer 6/18/2015
AVANIR Pharmaceuticals (AVNR) Announces Publication Of Positive Phase IIIb Results From AVP-825 Head-To-Head COMPASS Study In The Journal "Headache" 6/17/2015
Anthera Pharmaceuticals, Inc. (ANTH) Has Reached Enrollment Target In CHABLIS-SC1 Phase III Clinical Trial With Blisibimod 6/17/2015
RedHill Biopharma Ltd. (RDHL) Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease 6/16/2015
Ocular Therapeutix (OCUL) Begins Enrollment In Phase 3 Clinical Trial For DEXTENZA For The Treatment Of Allergic Conjunctivitis 6/16/2015
Tenax Therapeutics (TENX) Highlights New Scientific Publication Regarding The Potential Mortality Benefits Of Levosimendan In Septic Shock Patients 6/16/2015
Acorda Therapeutics (ACOR) Presents Data On Inhaled Levodopa Therapy CVT-301 At International Congress Of Parkinson's Disease And Movement Disorders 6/16/2015
Lundbeck Inc. (LUN.CO) Release: Analysis Of Responder Data From Clinical Trials Evaluating NORTHERA (Droxidopa) For The Treatment Of Symptomatic Neurogenic Orthostatic Hypotension 6/16/2015
AVEO Oncology (AVEO) Tumbles on Disappointing FDA Feedback for Tivozanib 6/15/2015
Pfizer (PFE) Failure on Phase III Pristiq Trial Unlikely to Hurt Bottom Line, Say Analysts 6/15/2015
RedHill Biopharma Ltd. (RDHL) Successfully Meets Primary Endpoint In Phase III Study Of RHB-105 For H. Pylori Infection 6/15/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Enters Into Manufacturing Agreement With PCT LLC, A Caladrius Biosciences Company, For US Production Of ICT-107 For Phase 3 Registration Trial 6/15/2015
Advaxis, Inc. Submits Special Protocol Assessment Request To FDA For ADXS-HPV Phase 3 Clinical Trial In Cervical Cancer 6/15/2015
Intra-Cellular Therapies, Inc. Reports Completion Of Enrollment With 450 Patients Randomized In The ITI-007-301 Phase III Clinical Trial For The Treatment Of Schizophrenia 6/15/2015
RedHill Biopharma Ltd. (RDHL) To Host Conference Call Today To Review Positive Phase III Top-Line Results With RHB-105 For H. Pylori Infection 6/15/2015
Innocoll, Inc. (INNL) Announces First Patient Dosed In The Cogenzia COACT-2 Phase III Study For The Treatment Of Diabetic Foot Infection 6/15/2015
Bial To Present Data On Opicapone At The 19th International Congress Of Parkinson's Disease And Movement Disorders 6/15/2015
Lipocine Inc. (LPCN) Announces Successful Completion Of Food Effect Study For LPCN 1021, An Oral Testosterone Product Candidate 6/15/2015
BioBlast Pharma (ORPN) Announces The Start Of A Phase III Study For Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD) 6/15/2015
AstraZeneca PLC (AZN) Announces Phase III Results For Lesinurad In Combination With Febuxostat In Tophaceous Gout Patients At European League Against Rheumatism Annual Congress (EULAR 2015) 6/15/2015
Pfizer (PFE) Reports Top Line Results From A Phase III Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation In Pediatric Patients With Major Depressive Disorder 6/12/2015
Novartis AG (NVS) Presents New Data At WCD That Shows Significant Efficacy Of Cosentyx In Patients With Psoriasis Of The Palms, Soles Of Feet And Nails 6/12/2015
Novartis AG (NVS) Data At European Hematology Association Show Increased PFS Benefit Of Farydak In New Subgroup Of Patients With Previously Treated Multiple Myeloma 6/12/2015
CTI BioPharma Release: Pacritinib Phase III Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis 6/12/2015
Sunesis Pharmaceuticals, Inc. (SNSS) Presents New Data From VALOR Evaluating Vosaroxin In Older Patients With Acute Myeloid Leukemia At The 20th Congress Of The European Hematology Association 6/12/2015
Celgene (CELG) Updated Results From MM-020/IFM 07-01 (First) Study Of REVLIMID Presented At European Hematology Association Annual Congress 6/12/2015
Eli Lilly (LLY) Release: Studies Show Psoriasis Patients Achieved Significant Levels Of Skin Clearance And Improved Quality Of Life After 12 Weeks Of Ixekizumab Treatment 6/11/2015
GW Pharma (GWPH) Initiates Second Phase III Pivotal Study Of Epidiolex (CBD) In Lennox-Gastaut Syndrome 6/11/2015
Genentech (RHHBY) Wins Breakthrough Nod From FDA for Systemic Sclerosis Treatment 6/11/2015
EXCLUSIVE: Genentech (RHHBY) Enrolling Patients in Phase III Actemra Trial, Company Tells BioSpace (DHX) 6/10/2015
CTI BioPharma And Baxter International (BAX) Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At European Hematology Association 6/10/2015
New Data Shows LEO Pharma A/S Investigational Psoriasis Treatment, Enstilar, Provides Rapid Itch Relief For Psoriasis Patients 6/10/2015
FDA Agrees With OncoGenex Pharmaceuticals Inc. (OGXI)' Phase 3 AFFINITY Protocol Amendment 6/10/2015
Merck & Co. (MRK) And Samsung Bioepis Announce Pivotal Phase III Studies For Investigational Biosimilars SB4, Enbrel (Etanercept), And SB2, Remicade (Infliximab), Met Primary Endpoints 6/10/2015
DalCor Hopes $250 Million Trial Can Revive Failed Roche (RHHBY) Heart Drug 6/10/2015
Bristol-Myers Squibb (BMY) Release: New Post Hoc Analyses Of Phase 3b Data Examine Treatment Withorencia (Abatacept) Plus Methotrexate (MTX) In Patients With Early Moderate To Severe Rheumatoid Arthritis (RA) And Markers Of Poor Prognosis 6/10/2015
Celgene (CELG) Release: Oral Presentation Evaluating Pooled Data On OTEZLA (Apremilast) For Long-Term Improvements In Enthesitis And Dactylitis To Be Presented At EULAR 6/10/2015
Biogen (BIIB) And Samsung Bioepis Announce New Data For Three Anti-TNF Biosimilar Development Candidates At EULAR 2015 Congress 6/10/2015
Alkermes (ALKS) Release: Aripiprazole Lauroxil Phase 3 Schizophrenia Study Results Published In Journal Of Clinical Psychiatry 6/10/2015
Symbiomix Doses First Patient In Confirmatory Phase 3 Pivotal Study Of Lead Drug Candidate SYM-1219 For Bacterial Vaginosis 6/9/2015
Jazz Pharmaceuticals (JAZZ) Release: Aytu BioScience Acquires Commercial-Stage Prostate Cancer Biologic 6/9/2015
Carbylan Therapeutics Completes Enrollment Of Phase III Pivotal Trial For Hydros-TA 6/9/2015
CytoDyn Cleared By FDA To Start Phase III Of First Injectable Antibody For HIV 6/9/2015
TherapeuticsMD, Inc.  (TXMD) Completes Enrollment In The Rejoice Trial, A Phase 3 Clinical Trial Of TX-004HR (estradiol In VagiCapTM) 6/9/2015
ASCO15: Amgen (AMGN) Was "Quiet Winner" at Cancer Conference, Says Analyst 6/8/2015
Titan Pharmaceuticals (TTP) Reports Positive Results From Phase 3 Study Of Probuphine For Opioid Addiction 6/8/2015
Novo Nordisk A/S (NVO) Release: New IDegLira Phase 3b Study Showed Statistically Significant HbA1c Reduction, Body Weight Change, And Lower Rate Of Hypoglycaemia Versus Insulin Glargine 6/8/2015
Braeburn Pharmaceuticals Reports Positive Results From Phase 3 Study Of Probuphine For Opioid Addiction 6/8/2015
Eli Lilly (LLY) Release: Study: Once-Weekly Trulicity (dulaglutide) Provides Greater Blood Sugar Reduction Compared To Once-Daily Victoza (liraglutide) In Japanese Patients After 52 Weeks 6/8/2015
PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy 6/8/2015
Eli Lilly (LLY) Release: Basal Insulin Peglispro Studies Demonstrate Superiority To Insulin Glargine Across Multiple Measures In People With Type 1 Diabetes 6/8/2015
Celator Pharmaceuticals, Inc. Announces Expansion of Clinical Study In Patients With Untreated Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) At High-Risk Of Treatment-Related Mortality 6/8/2015
Janssen Research & Development, LLC Release: New Data Show Initial Use Of Canagliflozin In Combination With Metformin Extended Release Significantly Improves A1C Levels In Adults With Type 2 Diabetes 6/8/2015
Eli Lilly (LLY)'s Basal Insulin Peglispro Shows Superiority To Insulin Glargine In Reducing Hba1c In People With Type 2 Diabetes 6/8/2015
Jazz Pharmaceuticals (JAZZ) Announces First Patients Enrolled In Phase 3 Clinical Development Program Evaluating JZP-110 As A Potential Treatment Of Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy Or With Obstructive Sleep Apnea (OSA) 6/8/2015
RedHill Biopharma Ltd. (RDHL) Completes Treatment Of Last Patient With RHB-105 In Phase III Study 6/8/2015
Chimerix (CMRX) Completes Targeted Enrollment For Brincidofovir Phase III SUPPRESS Trial 6/8/2015
Ultragenyx Pharmaceuticals (RARE) Announces Completion Of Enrollment In Phase III Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7 6/8/2015
DalCor Pharma Licenses A Late-Stage Investigational Cardiovascular Drug Following Major Scientific Discovery 6/8/2015
DalCor Pharma Licenses A Late-Stage Investigational Cardiovascular Drug Following Major Discovery By Montreal Heart Institute Scientists 6/8/2015
Resverlogix (RVX.TO) Reports On The Beneficial Effects Of RVX-208 On Glucose Metabolism In Prediabetes Mellitus At The American Diabetes Association's (ADA) Scientific Sessions In Boston, MA 6/8/2015
Intarcia Announces Presentations At American Diabetes Association Of Two Successful FREEDOM Phase 3 Trials For ITCA 650 -- A GLP-1 RA For Type 2 Diabetes 6/8/2015
CEL-SCI (CVM) Is Cleared To Start Patient Enrollment For Its Phase III Cancer Immunotherapy Trial In Thailand 6/8/2015
Sanofi (SAN.PA)'s Lyxumia (lixisenatide) Demonstrated Cardiovascular Safety In People With Type 2 Diabetes And High CV Risk 6/8/2015
AstraZeneca PLC (AZN)'s Booming Immuno-Onco Pipeline Validates Rebuffing Pfizer (PFE) 6/5/2015
Amgen (AMGN) Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease 6/5/2015
Horizon Pharma (HZNP) Initiates Phase 3 Trial Of ACTIMMUNE (interferon gamma-1b) For The Treatment Of People With Friedreich's Ataxia 6/5/2015
Ampio Pharmaceuticals, Inc. (AMPE) Announces Update Of STRIDE Study For The Investigation Of Pain Associated With Osteoarthritis 6/4/2015
ALK-Abello A/S Announces Top-Line Results From Its Partner Merck & Co. (MRK)'s North American Phase III Trial Of House Dust Mite SLIT-Tablet 6/4/2015
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) Improved Survival For Treatment-Naive Chronic Lymphocytic Leukemia Patients In Phase III RESONATE-2 Trial 6/4/2015
Argos Therapeutics, Inc. (ARGS) Release: Independent Data Monitoring Committee Recommends Continuation Of Pivotal ADAPT Phase III Clinical Trial Of AGS-003 For Metastatic Renal Cell Carcinoma 6/4/2015
AstraZeneca PLC (AZN) Gets Closer to a Decision on Suicide-Linked Drug, CEO Says 6/3/2015
ASCO15 EXCLUSIVE: Experimental Brain Cancer Drugs Heads to Phase II/III Trial This Year: DelMar Pharmaceuticals CEO 6/3/2015
Bristol-Myers Squibb (BMY) To Present Data From 14 Abstracts On Orencia (Abatacept) At The European League Against Rheumatism (EULAR) 2015 Annual Meeting 6/3/2015
RedHill Biopharma Ltd. (RDHL) Provides Update On Development Pipeline And Expected Timing For RHB-105 Phase III Top-Line Results 6/3/2015
Revance Therapeutics, Inc. (RVNC) To Initiate Two Key Trials For RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate 6/3/2015
AstraZeneca PLC (AZN) And Chi-Med Report Positive Data From Cancer Drug Combo 6/3/2015
Dipexium Pharmaceuticals (DPRX) Receives European Medicines Agency Scientific Advice On Clinical And Regulatory Pathway For Locilex Marketing Approval In European Union 6/2/2015
Janssen Research & Development Release: Trabectedin Improves Disease Control In Patients With Advanced Soft Tissue Sarcoma 6/2/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels Are Associated With Improvement Of Symptoms After Stem Cell Therapy In Patients With Ischemic Heart Failure 6/2/2015
ASCO15: Sunesis Pharmaceuticals, Inc. (SNSS) Announces Presentation Of VALOR Trial Subgroup Analysis At ASCO 2015 Annual Meeting 6/2/2015
Immunomedics, Inc. (IMMU) Announces Durable Responses In Metastatic Lung Cancer Patients Treated With Sacituzumab Govitecan 6/2/2015
ASCO15: AstraZeneca PLC (AZN) Updates On Immuno-Oncology Combo Development Program At ASCO 2015 6/2/2015
Immunomedics, Inc. (IMMU) Reports Labetuzumab Govitecan Is Active In Relapsed Metastatic Colorectal Cancer 6/2/2015
ASCO15: ERYtech Pharma Reported Full GRASPA Phase III Results In ALL And Provided Update On AML Phase IIb At ASCO 6/2/2015
Bristol-Myers Squibb (BMY) Release: Adding Investigational Agent Elotuzumab To Standard Treatment For Multiple Myeloma Significantly Reduced The Risk Of Disease Progression, According To New Phase III Data From ELOQUENT-2 Trial Published In The New England Journal of Medicine 6/2/2015
Boehringer Ingelheim’s Vargatef (Nintedanib) In Combination With Docetaxel Is Recommended As A Treatment Option Within Its Marketing Authorisation For Patents With A Common Type Of Lung Cancer 6/2/2015
ASCO15 EXCLUSIVE: Merck & Co. (MRK)’s Breast Cancer Drug Beats Chemo Rates and Will Roll Into Phase III, Says Investigator 6/1/2015
Bay Area's Heron (HRTX) Rockets as Nausea Drug Meets Goals in Phase III Study 6/1/2015



//-->